Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on May 14, 2025
aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis
GlobeNewswire
·
May 14, 2025
Preclinical data demonstrate ATYR0101’s unique anti-fibrotic mechanism through interaction with LTBP-1. ATYR0101 to be showcased in oral presentation at the American Thoracic Society (ATS) 2025 Respiratory Innovation Summit. SAN DIEGO, May 14, 2025 (GLOBE …
3Daughters Selects Connect Labs by Wexford - Baltimore for New Corporate Headquarters
GlobeNewswire
·
May 14, 2025
Access to Wexford Knowledge Community Platform Supports Creation of a Women’s Health Science Hub Presence within UMB BioPark Ecosystem and Provides Critical Connections for Growth BALTIMORE, May 14, 2025 (GLOBE NEWSWIRE) -- 3Daughters, Inc., a clinical …
Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal
GlobeNewswire
·
May 14, 2025
Published Research Demonstrates the Value of BVA in Meeting Key Goal of Identifying Anemia in Heart Failure Patients Oak Ridge, TN, May 14, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), Daxor Corporation, the global leader in blood volume …
FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301
GlobeNewswire
·
May 14, 2025
Pre-NDA Minutes from April 2, 2025, Meeting Received NDA Submission Planned this Summer KANSAS CITY, Kan., May 14, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) …
IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025
GlobeNewswire
·
May 14, 2025
Powerful B cell Targeting: INB-619 precisely targets and eliminates B cells from lupus patient samples, including harmful IgG1 and IgM antibodies, demonstrating potential as a treatment for autoimmune diseases Innovative Next Generation TCE Platform: INB- …
Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer
GlobeNewswire
·
May 14, 2025
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient has been dosed …
Hydreight Technologies to Present at Maxim Group’s 2025 Virtual Tech Conference & the CEM Bermuda Capital Event
GlobeNewswire
·
May 14, 2025
VANCOUVER, British Columbia and LAS VEGAS, May 14, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a fast-growing digital health platform transforming mobile and telehealth …
Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)
GlobeNewswire
·
May 14, 2025
Patient dosing completed in Phase 2 portion of Phase 2/3 RePOSA study evaluating IHL-42X oral treatment for OSA. End-of-study follow-up assessments on track for completion by May 17, 2025. Topline results expected in July 2025. NEW YORK and MELBOURNE, …
PharmaTher Unveils KetaVault™: A First-of-Its-Kind Portal to Accelerate Ketamine Research and Commercialization
GlobeNewswire
·
May 14, 2025
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on the research and commercialization of ketamine for unmet medical needs, today …
Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program
GlobeNewswire
·
May 14, 2025
-- New data showed setmelanotide achieved consistent, meaningful weight reduction -- -- Multiple presentations delivered at the first-ever Joint Congress between the European Society for Paediatric Endocrinology and the European Society of Endocrinology ( …
Emergent BioSolutions to Participate in Upcoming Investor Conferences
GlobeNewswire
·
May 14, 2025
GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of its executive management team will participate in the following investor conferences: RBC Global Healthcare Conference (New York, New …
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
GlobeNewswire
·
May 14, 2025
BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive …
Plus Therapeutics’ REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)
GlobeNewswire
·
May 14, 2025
Multiple long-term LM survivors in those patients receiving multiple doses of REYOBIQ RNA sequencing data show early tumor apoptosis and activation of innate immune responses Updated ReSPECT data presented at the 2025 Nuclear Medicine and Neurooncology …
Altimmune to Participate at Two Upcoming Investor Conferences
GlobeNewswire
·
May 14, 2025
GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the …
Anavex Life Sciences to Participate at Upcoming Healthcare Conferences
GlobeNewswire
·
May 14, 2025
NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, …
Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study
GlobeNewswire
·
May 14, 2025
Clear Improvement in Patient’s Skin Appearance Observed in Study after 12 weeks Compared to Baseline Key endpoints including Investigator’s Global Assessment (IGA), Modified Ichthyosis Area Severity (M-IASI) and Children’s Dermatology Life Quality Index ( …
PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update
GlobeNewswire
·
May 14, 2025
VERSATILE-003 Phase 3 Site Initiations Underway Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., May 14, 2025 (GLOBE …
Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update
GlobeNewswire
·
May 14, 2025
BETHESDA, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, …
Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder
GlobeNewswire
·
May 14, 2025
- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. - - Ann …
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025
GlobeNewswire
·
May 14, 2025
CARSON CITY, Nev., May 14, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver …